Abstract:Background The soil-transmitted nematodes (STNs) or helminths (hookworms, whipworms, large roundworms) infect the intestines of ~1.5 billion of the poorest peoples and are leading causes of morbidity worldwide. Only one class of anthelmintic or anti-nematode drugs, the benzimidazoles, is currently used in mass drug administrations, which is a dangerous situation. New anti-nematode drugs are urgently needed. Bacillus thuringiensis crystal protein Cry5B is a powerful, promising new candidate. Drug combinations, when properly made, are ideal for treating infectious diseases. Although there are some clinical trials using drug combinations against STNs, little quantitative and systemic work has been performed to define the characteristics of these combinations in vivo. Methodology/Principal findings Working with the hookworm Ancylostoma ceylanicum-hamster infection system, we establish a laboratory paradigm for studying anti-nematode combinations in vivo using Cry5B and the nicotinic acetylcholine receptor (nAChR) agonists tribendimidine and pyrantel pamoate. We demonstrate that Cry5B strongly synergizes in vivo with both tribendimidine and pyrantel at specific dose ratios against hookworm infections. For example, whereas 1 mg/kg Cry5B and 1 mg/kg tribendimidine individually resulted in only a 0%-6% reduction in hookworm burdens, the combination of the two resulted in a 41% reduction (P = 0.020). Furthermore, when mixed at synergistic ratios, these combinations eradicate hookworm infections at doses where the individual doses do not. Using cyathostomin nematode parasites of horses, we find based on inhibitory concentration 50% values that a strongylid parasite population doubly resistant to nAChR agonists and benzimidazoles is more susceptible or “hypersusceptible” to Cry5B than a cyathostomin population not resistant to nAChR agonists, consistent with previous Caenhorhabditis elegans results. Conclusions/Significance Our study provides a powerful means by which anthelmintic combination therapies can be examined in vivo in the laboratory. In addition, we demonstrate that Cry5B and nAChR agonists have excellent combinatorial properties—Cry5B combined with nAChR agonists gives rise to potent cures that are predicted to be recalcitrant to the development of parasite resistance. These drug combinations highlight bright spots in new anthelmintic development for human and veterinary animal intestinal nematode infections.

A phenotypic screen of the Global Health Priority Box identifies an insecticide with anthelmintic activity

Three Small Molecule Entities (MPK18, MPK334 and YAK308) with Activity against Haemonchus contortus In Vitro

An Extensive Comparison of the Effect of Anthelmintic Classes on Diverse Nematodes

In Vivo and in Vitro Studies of Cry5B and Nicotinic Acetylcholine Receptor Agonist Anthelmintics Reveal a Powerful and Unique Combination Therapy Against Intestinal Nematode Parasites

High-Throughput Phenotypic Assay to Screen for Anthelmintic Activity on Haemonchus contortus

Discovery of a Highly Synergistic Anthelmintic Combination That Shows Mutual Hypersusceptibility

High-throughput screening of more than 30,000 compounds for anthelmintics against gastrointestinal nematode parasites

An Inactivated Bacterium (paraprobiotic) Expressing Bacillus Thuringiensis Cry5B As a Therapeutic for Ascaris and Parascaris Spp. Infections in Large Animals.

Nitazoxanide: nematicidal mode of action and drug combination studies.

Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes

First Optimal Drug Combination for Roundworms

Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity

Global Health Priority Box: Discovering Flucofuron as a Promising Antikinetoplastid Compound

A new primary screening test for anthelmintics utilizing the parasitic stages of Nippostrongylus brasiliensis, in vitro

Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis

Structure-activity relationship and target investigation of 2-aryl quinolines with nematocidal activity

A new class of natural anthelmintics targeting lipid metabolism

Structure activity relationship and target prediction for ABX464 analogues in Caenorhabditis elegans

Thermal proteome profiling reveals Haemonchus orphan protein HCO_011565 as a target of the nematocidal small molecule UMW-868

In vivo anthelmintic potentials of Gongronema latifolium and Picralima nitida against gastrointestinal parasite (Heligmosomoides bakeri)

High-Throughput Screening of Entamoeba Identifies Compounds Which Target Both Life Cycle Stages and Which Are Effective Against Metronidazole Resistant Parasites